A Novel Broad-spectrum Antiviral Agent

一种新型广谱抗病毒药物

基本信息

  • 批准号:
    10323057
  • 负责人:
  • 金额:
    $ 29.07万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-01-01 至 2022-12-31
  • 项目状态:
    已结题

项目摘要

Summary Accelerating emergence and re-emergence of a wide array of viral epidemics has been a deadly feature of the 21st century. Potent or even effective therapies are rarely available to combat these diseases, and in general, the world remains unprepared to manage future outbreaks. The most recent outbreak of the Ebola virus resulted in over 11,000 fatalities, more than 20,000 orphans, and economic costs of >$32B (Worldbank), and instilled varying levels of fear in many more. But Ebola is not unique; in 2003 the global economic loss from the SARS virus was ~$40B (WHO). In 2017, there were travel and pregnancy restrictions within the Americas due to the Zika virus and its high correlation with the surge in the incidences of infant microcephaly. Currently, the world is experiencing unprecedented hardship from the life-threatening COVID-19 (SAR2-CoV-2) pandemic, which has already resulted in over 150,000 deaths worldwide, and for which there is no effective therapy or vaccine. Unfortunately, this is neither the first nor the last time the world is expected to be in this plight, unless a broadly acting first-line drug is available for rapid deployment. These outbreaks all resulted from RNA viruses, which remain a major unaddressed disease class. Arenaviruses (e.g. Lassa fever virus and Junin virus), coronaviruses (including SARS-COV-1, SARS-CoV-2, and MERS), and filoviruses (e.g. Ebola and Marburg viruses) are enveloped RNA viruses that cause severe and often fatal human diseases. Despite the global impact and toll on human lives, there are no effective treatment options or FDA-approved vaccines available to combat these devastating infections and they are accordingly classified as NIAID Priority Pathogens and are also on the select agent list of potential bioterrorism threats. This proposal seeks to address this highly significant, unmet clinical need by developing a broad spectrum antiviral agent (BSAA) that targets a fundamental host protein that is commonly subverted by multiple pathogenic virus families but is not essential for the host. In particular, we propose to target the human ER-Golgi intermediate compartment protein 53 kDa protein (ERGIC-53), a mannose-specific lectin that functions as an intracellular cargo receptor to facilitate the anterograde transport of selected cellular glycoprotein ligands in the early exocytic pathway. We have shown that ERGIC-53 is critically required for the propagation of arenaviruses, coronaviruses, and filoviruses. In particular, ERGIC-53 i) associates with the envelope glycoproteins encoded by these viruses as well as orthomyxoviruses and hantaviruses, ii) traffics to sites of virus budding, and iii) is incorporated into viral particles. In the absence of ERGIC-53, viral particles containing the normal array and quantity of viral structural proteins and genome are formed but are no longer infectious. Specifically, virions lacking ERGIC-53 are defective in their ability to attach to host cells. We have mapped the minimal domain within ERGIC-53 that is required for controlling virion infectivity and shown that extracellular targeting of this region potently neutralizes the infectivity of multiple pathogenic RNA viruses. Herein, we have presented strong scientific rationale for targeting ERGIC-53 and proof of concept data that extracellular targeting of ERGIC-53 is an effective antiviral target. Our development plan includes collaborating with Lake Pharma, a company with a proven track record in antibody generation technology. The successful development of potent antiviral monoclonal antibodies targeting ERGIC-53, would be groundbreaking in the treatment of viral outbreaks. Due to its broad spectrum activity and the expected safety of target modulation, ERGIC-53 targeting has the potential to be a first-line strategy against many RNA viruses.
总结 各种病毒性流行病的加速出现和重新出现一直是本世纪的一个致命特征, 21世纪世纪。有效的甚至是有效的治疗方法很少能用于对抗这些疾病,一般来说, 世界仍然没有做好应对未来疫情的准备。最近一次埃博拉病毒爆发导致 超过11,000人死亡,20,000多名孤儿,经济成本超过320亿美元(世界银行), 不同程度的恐惧但埃博拉病毒并不是独一无二的; 2003年,SARS造成的全球经济损失 病毒约为400亿美元(世卫组织)。在2017年,由于美国的移民政策, 寨卡病毒及其与婴儿小头畸形发病率激增的高度相关性。目前,世界 经历了威胁生命的COVID-19(SAR 2-CoV-2)大流行带来的前所未有的困难, 已经导致全球超过15万人死亡,并且没有有效的治疗方法或疫苗。 不幸的是,这既不是第一次,也不是最后一次,世界预计将在这种困境,除非广泛的 可快速部署一线药物。这些爆发都是由RNA病毒引起的, 仍然是一个主要的未解决的疾病类别。沙粒病毒(例如拉沙热病毒和朱宁病毒),冠状病毒 (包括SARS-COV-1、SARS-CoV-2和MERS)和丝状病毒(例如埃博拉病毒和马尔堡病毒) 有包膜的RNA病毒,可引起严重且往往致命的人类疾病。尽管全球性的影响和损失, 人的生命,没有有效的治疗选择或FDA批准的疫苗可用于对抗这些 毁灭性的感染,因此它们被归类为NIAID优先病原体, 潜在生物恐怖威胁的特工名单 该提案旨在通过开发一种广泛的 一种抗病毒剂(BSAA),靶向一种基本的宿主蛋白,该蛋白通常被多种病原体破坏 病毒家族,但对宿主不是必需的。特别是,我们建议靶向人类ER-高尔基体中间体 隔室蛋白53 kDa蛋白(ERGIC-53),一种甘露糖特异性凝集素,作为细胞内 货物受体,以促进选择的细胞糖蛋白配体在早期胞外 通路我们已经证明,ERGIC-53是沙粒病毒、冠状病毒、 和丝状病毒。特别地,ERGIC-53 i)与这些病毒编码的包膜糖蛋白结合 以及正粘病毒和汉坦病毒,ii)向病毒出芽位点的运输,和iii)并入 病毒颗粒在不存在ERGIC-53的情况下,含有正常阵列和病毒量的病毒颗粒可被检测到。 结构蛋白和基因组形成,但不再具有传染性。具体地说,缺乏ERGIC-53的病毒体 在附着于宿主细胞的能力上有缺陷。我们已经映射了ERGIC-53中的最小域, 是控制病毒体感染性所必需的,并显示该区域的细胞外靶向有效地中和了 多种病原性RNA病毒的感染性。 在此,我们提出了靶向ERGIC-53的强有力的科学依据和概念数据证明, ERGIC-53的细胞外靶向是有效的抗病毒靶点。我们的发展计划包括 与Lake Pharma合作,Lake Pharma是一家在抗体生成技术方面拥有良好记录的公司。 成功开发针对ERGIC-53的有效抗病毒单克隆抗体将是 在病毒爆发的治疗方面具有开创性。由于其广谱活性和预期的安全性 在靶点调节方面,ERGIC-53靶向有可能成为对抗许多RNA病毒的一线策略。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jason W. Botten其他文献

Jason W. Botten的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jason W. Botten', 18)}}的其他基金

The role of mammarenavirus defective interfering particles in protecting host fitness and the host-driven post-translational modifications that regulate their formation and function
哺乳动物病毒缺陷干扰颗粒在保护宿主健康中的作用以及调节其形成和功能的宿主驱动的翻译后修饰
  • 批准号:
    10514041
  • 财政年份:
    2022
  • 资助金额:
    $ 29.07万
  • 项目类别:
The role of mammarenavirus defective interfering particles in protecting host fitness and the host-driven post-translational modifications that regulate their formation and function
哺乳动物病毒缺陷干扰颗粒在保护宿主健康中的作用以及调节其形成和功能的宿主驱动的翻译后修饰
  • 批准号:
    10687000
  • 财政年份:
    2022
  • 资助金额:
    $ 29.07万
  • 项目类别:
A Novel Broad-spectrum Antiviral Agent
一种新型广谱抗病毒药物
  • 批准号:
    10156116
  • 财政年份:
    2021
  • 资助金额:
    $ 29.07万
  • 项目类别:
Deep sequencing the lymphocytic choriomeningitis arenavirus quasispecies to identify and functionally validate the molecular signature ofdefective interfering particles
对淋巴细胞脉络膜脑膜炎沙粒病毒准种进行深度测序,以识别和功能验证缺陷干扰颗粒的分子特征
  • 批准号:
    10043049
  • 财政年份:
    2020
  • 资助金额:
    $ 29.07万
  • 项目类别:
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine
四价登革热减毒活疫苗的保护和持久性机制
  • 批准号:
    10334565
  • 财政年份:
    2019
  • 资助金额:
    $ 29.07万
  • 项目类别:
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine
四价登革热减毒活疫苗的保护和持久性机制
  • 批准号:
    10570174
  • 财政年份:
    2019
  • 资助金额:
    $ 29.07万
  • 项目类别:
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue Vaccine
四价登革热减毒活疫苗的保护和持久性机制
  • 批准号:
    10089397
  • 财政年份:
    2019
  • 资助金额:
    $ 29.07万
  • 项目类别:
A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome
一种治疗汉坦病毒心肺综合征的人单克隆抗体疗法
  • 批准号:
    10611715
  • 财政年份:
    2017
  • 资助金额:
    $ 29.07万
  • 项目类别:
HANTAVIRUS AND ARENAVIRUS HOST-PATHOGEN INTERACTIONS
汉坦病毒和沙粒病毒宿主-病原体相互作用
  • 批准号:
    8360777
  • 财政年份:
    2011
  • 资助金额:
    $ 29.07万
  • 项目类别:
Identification of Novel Arenavirus Protein-Host Cellular Protein Interactions
新型沙粒病毒蛋白-宿主细胞蛋白相互作用的鉴定
  • 批准号:
    8077445
  • 财政年份:
    2010
  • 资助金额:
    $ 29.07万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 29.07万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了